Data supports using this as first line therapy showing durable antitumor activity and manageable toxicity, thankfully not common tumors.
The combination of cabozantinib/nivolumab remains a powerful combination in the RCC space. This article brings together data on histology and genomics to predict response in NCC-RCC with improved efficacy in tumors expressing NF2 and FH, and decreased activity in chromophobic histology. The role and utilization of data continue to evolve and become prevalent in day-to-day practice.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
